Amgen pays $290M to exit osteoporosis drug deal
Amgen will pay $290 million to end its collaboration with British drugmaker GlaxoSmithKline to commercialize the osteoporosis drug denosumab in certain markets outside the U.S.
A prescription for team work: Conejo doctors band together against UCLA incursion
Choice Health Associates is a loose affiliation of physicians in private practice who have teamed up to better compete with big out-of-town providers.
Cashing out: Bank of America consolidates Simi operations
Bank of America has shed a 1 million-square-foot portfolio of former Countrywide Financial Corp. office buildings for $200 million and plans to consolidate its Simi Valley campus.
Ceres to plow $23M raise into sorghum tests
Thousand Oaks-based energy crop firm Ceres has raised $23 million that it hopes will help it to break even as it continues testing its seeds in Brazil.
Thousand Oaks law seminars focus on big questions in biotech
Organizers promise a steady progression from relatively anodyne topics like 3-D printers and intellectual property to touchier subjects, such as genetically engineered salmon, how animals are treated in biotech research and what ethical and legal obligations biotech researchers have when they appropriate and commercialize molecules traditionally used by indigenous cultures.
